Home > Internet > RGFP966 Developers Join Forces

RGFP966 Developers Join Forces

Added: (Wed Jan 03 2018)

Pressbox (Press Release) - There are two main reasons for the reluctance of many European health authorities to include influenza vaccination in their national vaccination programmes. The first is their widespread conviction that, although very common, influenza in healthy children is always very mild and therefore does not need to be prevented by vaccination. The second is that there are doubts concerning the real ability of the available vaccines to evoke a protective immune response in children, particularly those in the first years of life. Data regarding the total burden of childhood influenza collected over the last 10?years [1�C7] indicate that the first assumption is probably wrong, and that influenza in healthy children (particularly the youngest) gives rise to a substantial medical and economic burden that largely justifies prevention. However, it is significantly more difficult to establish whether selleck chemicals llc the available vaccines are effective enough to support their universal use in healthy children, and two recent meta-analyses have reached opposing conclusions [16,17]. As the course of influenza can be worst in children aged <5?years, the main aim of this review is to discuss whether the currently available data concerning the efficacy 3-mercaptopyruvate sulfurtransferase of influenza vaccines justifies their universal use in healthy children of this age. Trivalent inactivated vaccines (TIVs; split-virus and subunit TIVs) are the only injectable preparations that are licensed for paediatric use throughout the world. Modern TIVs are very different from the monovalent products containing one whole killed virus (mainly type A) that were first prepared more than 40?years ago [18] because they usually contain fractions of three viruses, the most important of which in immunological terms are the haemagglutinin of each. The three viral strains are chosen every year on the basis of WHO indications of the most probable causes of seasonal influenza epidemics. Throughout the world, TIVs are only licensed for children aged ��6?months. Moreover, it is recommended that previously unvaccinated children until the age of 9?years in some countries and until the age of 3?years in other countries should be given two TIV doses 1?month apart [8,9]. However, antibody production after TIV administration increases with age: Walter et?al. [19] studied children Selinexor cell line aged 6�C23?months in two consecutive years, and found that significantly higher proportions of the older subjects achieved seroprotective antibody concentrations or a four-fold increase in geometric mean titres. Nevertheless, the majority of the youngest children had significantly high levels of antibodies against influenza antigens, which suggests that, although the correlate of protection for children has never been established, some protective efficacy is possible in younger subjects [19].

Submitted by:
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.